Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Small-Cap with Disruptive Real Estate Agent Platform Provides 'Blue-Sky' Potential

As the groundbreaking real-estate industry platform provides "disruption from the inside," the company moves to monetize its asset. Publicly traded small-cap RESAAS Services Inc. (RSS:TSX.V; RSASF:OTCQB) is changing the way real estate professionals do business. Its a...
Streetwise Reports | March 1, 2019 |

A Deep Dig into the Largest VMS District in the World

For metals & mining investors, copper has long been one of the planet’s most in-demand metals. But the shine on this versatile industrial metal has dulled over the past number of years, as overall, investment hasn’t kept up with consumption a...
Dave Jackson | January 3, 2020 |

Navidea Shares Jump 60% on Phase 2b Rheumatoid Arthritis Trial Results

Shares of Navidea Biopharmaceuticals traded 60% higher today on extremely high relative volume after the firm released data from its Phase 2b Rheumatoid Arthritis Tc 99m Tilmanocept Planar Imaging study. Developer of precision immunodiagnostic agents and immunotherape...
Streetwise Reports | October 30, 2019 |

Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax

Shares of Paratek Pharmaceuticals traded 40% higher today after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax. Late yesterday afternoon, biopharmaceutical company Paratek Pharmaceuti...
Streetwise Reports | December 20, 2019 |

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were ...
Streetwise Reports | January 17, 2020 |

Imagin Medical Poised for Breakout with Bladder Cancer Detection Device in FDA Approval Process

A new advancement in bladder-related endoscopic surgery is endorsed and de-risked. You don't often hear about it, but bladder cancer is the sixth most common cancer in the U.S., with approximately 80,000 cases reported every year, and some 600,000 Americans living in ...
Streetwise Reports | November 13, 2019 |

Threat Detection Company Branching Out with Multiple Technologies

Company continues to add technologies, turning it into a total solutions provider. Patriot One Technologies Inc. (PAT:TSX.V; PTOTF:OTCQX) , developer of the PATSCAN software and sensor solutions for the covert detection of weapons threats, has spent the last year turnin...
Streetwise Reports | February 27, 2019 |

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. Clinical-stage biopharmaceutical company Mersana Therapeuti...
Streetwise Reports | May 28, 2020 |

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
Streetwise Reports | September 30, 2019 |

Cannabis testing: the new frontier

The legalization of cannabis in Canada was heralded by growers, dispensaries and users throughout the country, some of whom had been calling for an end to the prohibition of cannabis for years. What many had not anticipated was the need for a rigorous system for tes...
Richard (Rick) Mills | March 12, 2019 |
1 2 3 4 5 6 7 8 9 10 ...